{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:02:57Z","timestamp":1791277377221,"version":"4.1.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1097\/gme.0b013e31817d5372","type":"journal-article","created":{"date-parts":[[2009,1,8]],"date-time":"2009-01-08T03:14:53Z","timestamp":1231384493000},"page":"132-140","source":"Crossref","is-referenced-by-count":28,"title":["Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women"],"prefix":"10.1097","volume":"16","author":[{"given":"Richard E.","family":"Hedrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald T.","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Koltun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark B.","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence J.","family":"Lambrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-22-20210227","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0749-0690(02)00143-X","article-title":"The use of estrogen in older women.","volume":"19","author":"Birge","year":"2003","journal-title":"Clin Geriatr Med"},{"key":"R2-22-20210227","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1517\/17425247.3.2.191","article-title":"Delivery systems for hormone replacement therapy.","volume":"3","author":"Fraser","year":"2006","journal-title":"Expert Opin Drug Deliv"},{"key":"R3-22-20210227","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1592\/phco.21.5.464.34486","article-title":"Urogenital atrophy: prevention and treatment.","volume":"21","author":"Willhite","year":"2001","journal-title":"Pharmacotherapy"},{"key":"R4-22-20210227","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/aje\/152.5.463","article-title":"Relation of demographic and lifestyle factors to symptoms in a multi-racial\/ethnic population of women 40-55 years of age.","volume":"152","author":"Gold","year":"2000","journal-title":"Am J Epidemiol"},{"key":"R5-22-20210227","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3949\/ccjm.71.7.578","article-title":"Treatment options for menopausal hot flashes.","volume":"71","author":"Sikon","year":"2004","journal-title":"Cleve Clin J Med"},{"key":"R6-22-20210227","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMp030038","article-title":"Postmenopausal hormones-therapy for symptoms only.","volume":"348","author":"Grady","year":"2003","journal-title":"N Engl J Med"},{"key":"R7-22-20210227","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"R8-22-20210227","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"R9-22-20210227","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jama.297.13.1465","article-title":"Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.","volume":"297","author":"Rossouw","year":"2007","journal-title":"JAMA"},{"key":"R10-22-20210227","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1525-1497.2006.00389.x","article-title":"Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis.","volume":"21","author":"Salpeter","year":"2006","journal-title":"J Gen Intern Med"},{"key":"R11-22-20210227","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/jama.289.5.537","article-title":"FDA orders estrogen safety warnings: agency offers guidance for HRT use.","volume":"289","author":"Stephenson","year":"2003","journal-title":"JAMA"},{"key":"R12-22-20210227","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/gme.0b013e31803167ab","article-title":"Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society.","volume":"14","year":"2007","journal-title":"Menopause"},{"issue":"Suppl 12B","key":"R14-22-20210227","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.amjmed.2005.09.035","article-title":"Vasomotor symptom relief versus unwanted effects: role of estrogen dosage.","volume":"118","author":"Ettinger","year":"2005","journal-title":"Am J Med"},{"issue":"3","key":"R15-22-20210227","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1385\/ENDO:24:3:217","article-title":"The rationale for low-dose hormonal therapy.","volume":"24","author":"Lobo","year":"2004","journal-title":"Endocrine"},{"key":"R16-22-20210227","first-page":"S1","article-title":"Transdermal estrogen therapy: evidence and update.","volume":"32","author":"Simon","year":"2007","journal-title":"Female Patient"},{"key":"R17-22-20210227","first-page":"293","article-title":"Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches. A randomized, double-blind placebo-controlled study.","volume":"50","author":"De Aloysio","year":"2000","journal-title":"Arzneimittelforschung"},{"key":"R18-22-20210227","first-page":"311","article-title":"Considerations in the choice of oral vs. transdermal hormone therapy: a review.","volume":"49","author":"Minkin","year":"2004","journal-title":"J Reprod Med"},{"key":"R19-22-20210227","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1067\/mob.2001.109656","article-title":"The pharmacokinetics and efficacy of different estrogens are not equivalent.","volume":"184","author":"Ansbacher","year":"2001","journal-title":"Am J Obstet Gynecol"},{"key":"R20-22-20210227","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/CIRCULATIONAHA.106.642280","article-title":"Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.","volume":"115","author":"Canonico","year":"2007","journal-title":"Circulation"},{"key":"R21-22-20210227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.maturitas.2005.05.003","article-title":"New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.","volume":"52","author":"Modena","year":"2005","journal-title":"Maturitas"},{"key":"R22-22-20210227","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4158\/EP.12.3.315","article-title":"American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause.","volume":"12","year":"2006","journal-title":"Endocr Pract"},{"key":"R24-22-20210227","first-page":"228","article-title":"Postmenopausal vaginal atrophy and atrophic vaginitis.","volume":"314","author":"Pandit","year":"1997","journal-title":"Am J Med Sci"},{"key":"R25-22-20210227","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/jama.1982.03330040033027","article-title":"Estrogen deprivation and vaginal function in postmenopausal women.","volume":"248","author":"Semmens","year":"1982","journal-title":"JAMA"},{"key":"R26-22-20210227","first-page":"700","article-title":"Vaginal pH and parabasal cells in postmenopausal women.","volume":"94","author":"Brizzolara","year":"1999","journal-title":"Obstet Gynecol"},{"key":"R27-22-20210227","doi-asserted-by":"crossref","first-page":"S257","DOI":"10.1016\/S0002-9378(98)70558-7","article-title":"The clinical platform for the 17-estradiol vaginal releasing ring.","volume":"178","author":"Bachmann","year":"1998","journal-title":"Am J Obstet Gynecol"},{"key":"R28-22-20210227","doi-asserted-by":"crossref","first-page":"643","DOI":"10.5694\/j.1326-5377.2007.tb01084.x","article-title":"HRT: a reappraisal of the risks and benefits.","volume":"186","author":"MacLennan","year":"2007","journal-title":"Med J Aust"},{"key":"R29-22-20210227","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/13697130400012239","article-title":"Transdermal hormone therapy: gels and patches.","volume":"7","author":"Samsioe","year":"2004","journal-title":"Climacteric"},{"key":"R30-22-20210227","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(03)14066-4","article-title":"Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk.","volume":"362","author":"Scarabin","year":"2003","journal-title":"Lancet"},{"key":"R31-22-20210227","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1055\/s-0037-1615643","article-title":"Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.","volume":"85","author":"Vehkavaara","year":"2001","journal-title":"Thromb Haemost"},{"key":"R32-22-20210227","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0025-6196(11)61002-1","article-title":"Historical perspectives in postmenopausal hormone therapy: defining the right dose and duration.","volume":"82","author":"Warren","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"R33-22-20210227","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1089\/jwh.2006.0311","article-title":"Bioidentical hormone therapy: a review of the evidence.","volume":"16","author":"Cirigliano","year":"2007","journal-title":"JWomens Health"},{"key":"R34-22-20210227","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0378-5122(00)00222-X","article-title":"Comparative absorption and variability in absorption of estradiol from a transdermal gel and a novel matrix-type transdermal patch.","volume":"38","author":"Jarvinen","year":"2001","journal-title":"Maturitas"},{"key":"R35-22-20210227","first-page":"758","article-title":"Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol.","volume":"77","author":"Scott","year":"1991","journal-title":"Obstet Gynecol"},{"key":"R36-22-20210227","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0378-5122(01)00239-0","article-title":"Comparison of pharmacokinetic profiles of a 17 -estradiol gel 0.6 mg\/g (Gelestra) with a transdermal delivery system (Estraderm TTS 50) in postmenopausal women at steady state.","volume":"40","author":"Paoletti","year":"2001","journal-title":"Maturitas"},{"key":"R37-22-20210227","first-page":"64","article-title":"A comparison of transdermal and oral HRT for menopausal symptom control.","volume":"51","year":"2006","journal-title":"Int J Fertil Womens Med"},{"key":"R38-22-20210227","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/136218079500100211","article-title":"C.P.R. Why do British women start and stop hormone replacement therapy?","volume":"1","author":"Hope","year":"1995","journal-title":"J Br Menopause Soc"},{"key":"R39-22-20210227","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/archinte.159.13.1458","article-title":"Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women.","volume":"159","author":"Col","year":"1999","journal-title":"Arch Intern Med"},{"key":"R40-22-20210227","first-page":"9","article-title":"Why individualizing hormone therapy is crucial: putting the results of the WHI trial into perspective.","volume":"7","author":"Notelovitz","year":"2002","journal-title":"Medscape Womens Health"}],"container-title":["Menopause"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00042192-200916010-00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:30:10Z","timestamp":1786037410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00042192-200916010-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/gme.0b013e31817d5372","relation":{},"ISSN":["1072-3714"],"issn-type":[{"value":"1072-3714","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}